BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Has Average Target Price of $89.17 According to Brokerages

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been assigned a consensus rating of “Moderate Buy” from the twenty-four brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation, fifteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $89.17.

BMRN has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “neutral” rating and set a $60.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, September 10th. Barclays boosted their target price on shares of BioMarin Pharmaceutical from $105.00 to $111.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Royal Bank Of Canada reduced their price target on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Wall Street Zen raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, William Blair raised shares of BioMarin Pharmaceutical to a “hold” rating in a research note on Wednesday, September 23rd.

BioMarin Pharmaceutical Trading Down 2.2%

Shares of BMRN stock opened at $57.18 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. The company has a market cap of $11.07 billion, a price-to-earnings ratio of 154.54, a PEG ratio of 0.41 and a beta of 0.22. The stock has a 50 day simple moving average of $64.13 and a 200-day simple moving average of $58.64. BioMarin Pharmaceutical has a 1-year low of $49.26 and a 1-year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business’s revenue was up 20.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities research analysts expect that BioMarin Pharmaceutical will post 4.1 EPS for the current fiscal year.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported five-year Phase 3 data for POMBILITI® (cipaglucosidase alfa-atga) plus OPFOLDA® (miglustat) in adults with late-onset Pompe disease. Patients maintained motor function, including walking ability, while respiratory function remained relatively stable; no new safety signals were identified. The results support the combination’s durability and may strengthen its long-term commercial position. BioMarin Announces Five-Year Phase 3 Data for POMBILITI + OPFOLDA
• Positive Sentiment: The long-term evidence is particularly relevant for BioMarin because sustained motor and lung benefits could support physician confidence, patient retention and continued adoption of POMBILITI plus OPFOLDA in the rare-disease market. BioMarin Reports Five-Year Pompe Disease Data Showing Durable Motor Function
• Neutral Sentiment: BioMarin also partnered with Profluent to use artificial intelligence in designing novel medicines. The deal could expand future discovery capabilities, but it is an early-stage development and has limited near-term earnings impact. Profluent and BioMarin Partner on AI-Designed Medicines
• Positive Sentiment: A newly granted global license to Ascendis Therapeutics is expected to provide BioMarin with royalty revenue, offering a potentially useful source of recurring, asset-light income. BioMarin Grants Ascendis Global License
• Negative Sentiment: Shares declined following the Pompe data announcement, suggesting investors may have been looking for a more significant surprise or immediate financial upgrade. The reaction also reflects the risk that strong clinical results are already partly reflected in expectations, particularly with BioMarin trading at a high earnings multiple. BioMarin Adds Five-Year Evidence for POMBILITI + OPFOLDA

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in BMRN. Parkside Financial Bank & Trust increased its position in shares of BioMarin Pharmaceutical by 70.3% during the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 187 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in BioMarin Pharmaceutical in the 2nd quarter valued at $39,000. Keating Financial Advisory Services Inc. acquired a new stake in BioMarin Pharmaceutical during the 2nd quarter worth $56,000. Wick Capital Partners LLC acquired a new stake in BioMarin Pharmaceutical during the 4th quarter worth $73,000. Finally, Parallel Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical by 33.9% during the first quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company’s stock worth $100,000 after buying an additional 448 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.